|
Vol 58(2024) N 2 p. 255-265; DOI 10.1134/S002689332402016X  A.N. Uvarova1*, E.A. Tkachenko2,3, E.M. Stasevich1, E.A. Bogomolova2,4, E.A. Zheremyan2,3, D.V. Kuprash1,3,4, K.V. Korneev1,5 The rs2564978(T) Allele Associated with Severe Influenza A Disrupts the Binding Site for Myeloid Differentiation Factor PU.1 and Reduces CD55/DAF Gene Promoter Activity in Macrophages 1Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia2Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, 119991 Russia 3Biological Faculty, Moscow State University, Moscow, 119234 Russia 4Department of Molecular and Biological Physics, Moscow Institute of Physics and Technology, Moscow, 141701 Russia 5National Research Center for Hematology, Ministry of Health of the Russian Federation, Moscow, 125167 Russia *uvarowww@gmail.com Received - 2023-09-27; Revised - 2023-10-23; Accepted - 2023-10-23 The complement inhibitor CD55/DAF is expressed on many cell types. Dysregulation of CD55 expression is associated with increased disease severity in influenza A infection and vascular complications in pathologies that involve excessive activation of the complement system. A luciferase reporter system was used to functionally analyze the single nucleotide polymorphism rs2564978 in the U937 human promonocytic cell line. The polymorphism is in the promoter of the CD55 gene, and its minor allele T is associated with a severe course of influenza A(H1N1)pdm09. A decreased activity of the CD55 promoter carrying the minor rs2564978(T) allele was observed in activated U937 cells, which provide a cell model of human macrophages. Using bioinformatics resources, PU.1 was identified as a potential transcription factor that may bind to the CD55 promoter at the rs2564978 site in an allele-specific manner. The involvement of PU.1 in modulating CD55 promoter activity was verified by a PU.1 genetic knockdown with small interfering RNAs under specific monocyte activation conditions. CD55/DAF, SNP, PU.1/SPI1, complement system |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
